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CONCLUSION: Patients diagnosed with atrial ﬂutter incur sig-
niﬁcant health care costs and resource utilization. This analysis
of atrial ﬂutter patients is the ﬁrst step towards understanding
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OBJECTIVES: To determine the total direct health care costs of
patients newly diagnosed with chronic non-valvular atrial ﬁbril-
lation (CNVAF) before diagnosis and after a transient ischemic
attack (TIA), ischemic stroke (IS) or major bleed (MB).
METHODS: This retrospective, observational cohort study uti-
lized medical and pharmacy claims from a large, geographically
diverse managed care organization to identify patients with ≥two
atrial ﬁbrillation (AF) claims between January 1, 2001–June 30,
2002. Continuously enrolled members with no evidence of AF
(ICD-9-CM = 427.31) or warfarin claims 12 months prior to 
the index AF claim were followed for ≥six-months until ﬁrst
TIA/IS/MB (EVENT) or study end. Total direct health care 
costs for all patients were assessed pre- and post-AF index 
claim. For the subset of patients with an EVENT, total health
care costs were also assessed pre- and post-EVENT (from 
index AF up to EVENT, and EVENT to study end). RESULTS:
Of 3891 incidence CNVAF patients, 62% were male and 55%
were ≥65 years. Pre- and post-AF total direct health care costs
were $400 and $1073 per patient month (PPM) respectively. 
The 448 of 3891 (12%) patients with an EVENT had post-
EVENT total direct health care costs of $2311 PPM. Approxi-
mately 46% of all events occurred £one-month after the index
AF claim. CONCLUSIONS: In this population, post-AF total
direct health care costs were 2.7 times greater than pre-AF total
health care costs. For the subgroup of patients with a subsequent
TIA, IS or MB, post-EVENT total direct health care costs
increased 5.8 times from pre-AF costs with nearly half of the
events occurring within one month of AF diagnosis. Identiﬁca-
tion and treatment of CNVAF patients at risk for a cardiovas-
cular event can result in substantially lower costs to the health
care system.
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Atrial ﬁbrillation (AF) develops in some 30% of patients fol-
lowing cardiac surgery, signiﬁcantly increasing hospital length 
of stay (LOS) and costs. Previous data suggested that amio-
darone was cost-effective overall in preventing postoperative 
AF. OBJECTIVES: Using recently published epidemiological 
and clinical data, the purpose of this analysis was to assess 
the cost-effectiveness of amiodarone prophylaxis in speciﬁc
patient subgroups undergoing cardiac surgery. METHODS: A 
literature-based decision analytic model was developed from a
US payer perspective. The time horizon was the duration of
cardiac surgery hospitalization. Amiodarone plus standard of
care (beta-blocker prophylaxis) was compared to standard 
of care alone in the following patient AF risk groups: 1) age ≥
70 years, 50–69 years, and 30–49 years; 2) history of AF; and
3) concurrent valve surgery. The cost of amiodarone, LOS, physi-
cian services, adverse events, and AF treatment were included.
Sensitivity analyses were conducted to test the robustness of 
the analysis. RESULTS: In all patient populations, a 26% AF
risk reduction rate was used for amiodarone with a range of
18%–72%. Total LOS in the intensive care unit (ICU) and non-
ICU was 9.20 (ICU/non-ICU: 2.86/6.34) days in AF patients
versus 6.40 (ICU/non-ICU: 2.23/4.17) days in non-AF patients.
Amiodarone was dominant over standard of care alone in high-
risk patients (age ≥ 70 years, history of AF, or concurrent valve
surgery). The cost of amiodarone per AF event prevented was
$1,793 in patients 50–69 years and increased to $19,424 in
patients 30–49 years. The results were highly sensitive to a
change in amiodarone efﬁcacy and LOS, but less sensitive to
amiodarone drug cost. CONCLUSION: Based on this model,
amiodarone can be considered cost effective in patients under-
going cardiac surgery depending on the willingness-to-pay
threshold employed. Selection of high-risk patients improves the
cost-effectiveness ratio compared to patients with low/moderate
risk.
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OBJECTIVE: To examine race and gender cost differences asso-
ciated with treating atrial ﬁbrillation (AF) in the inpatient setting.
METHODS: This retrospective study analyzed nationally repre-
sentative hospital discharge data from the 2001 Health Care
Cost and Utilization Project (HCUP) database. The impact of
race and gender on costs of treating AF as a primary diagnosis
(ICD-9 427.31) and as a comorbid diagnosis was examined.
Using the ﬁve most frequent principal discharge diagnoses (CAD,
CHF, pneumonia, COPD, MI) with AF as a comorbid diagnosis
(case), a case/control analysis was performed to estimate annual
incremental costs of AF. Cases were matched to controls on age,
gender, race, principal discharge diagnosis, and hospital bed size.
Ordinary least squares regression was used with the following
covariates: age, gender, race, payer, bed size, emergency admis-
sion, unrelated surgery, and comorbidities. RESULTS: There
were 348,000 hospitalizations for AF as principal diagnosis with
a cost of $2.56 billion. Among the top ﬁve HCUP diagnoses with
AF as a comorbid diagnosis, there were 547,000 hospitalizations
with an incremental cost of $1.5 billion. Although race and
gender did not signiﬁcantly affect the costs of hospitalizations
for AF as a principal diagnosis, non-white race was associated
with signiﬁcantly (P < 0.001) higher costs among the top ﬁve
HCUP diagnoses with AF as a comorbid diagnosis with costs
ranging from $1216 (CHF) to $2537 (MI) per hospitalization.
Female gender was associated with signiﬁcantly increased costs
for pneumonia and COPD, but decreased costs for CHF and MI.
CONCLUSIONS: Neither gender nor race affect costs when
treating AF as a principal diagnosis. Non-white race is associ-
ated with higher costs in treating top ﬁve HCUP diagnoses with
comorbid AF.
